Importance and limitations of chemotherapy among the available treatments for gastrointestinal tumours.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Anti-Cancer Agents in Medicinal Chemistry

• Publication date

  2009-01-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/187152009787313828PMID 19199863
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.

  2008cited by this paper
• A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.

  2008cited by this paper
• Gastric cancer.

  2008cited by this paper
• Cancer Statistics, 2008

  2008cited by this paper
• Capecitabine and oxaliplatin for advanced esophagogastric cancer.

  2008cited by this paper
• The mismatch repair‐mediated cell cycle checkpoint response to fluorodeoxyuridine

  2008cited by this paper
• Detection and endoscopic therapy of early esophageal adenocarcinoma

  2008cited by this paper
• Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 25-27, 2008.

  2008cited by this paper
• Adjuvant therapies for colorectal cancer.

  2007cited by this paper
• Racial variation in colorectal polyp and tumor location.

  2007cited by this paper
• Medical treatment for advanced gastroesophageal adenocarcinoma

  2007cited by this paper
• A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes.

  2007cited by this paper
• Extended resection for pancreatic adenocarcinoma.

  2007cited by this paper
• Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

  2007cited by this paper
• ABCG2 Expression Is an Independent Unfavorable Prognostic Factor in Esophageal Squamous Cell Carcinoma

  2007cited by this paper
• Neuroendocrine tumors. Peptide receptor radionuclide therapy.

  2007cited by this paper
• Lymph node metastases of adenocarcinoma of the esophagus and esophagogastric junction.

  2007cited by this paper
• A Randomized Phase 2 Trial of Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer: Gemcitabine Alone Versus Gemcitabine Combined with Cisplatin

  2007cited by this paper
• Phospho Akt mediates multidrug resistance of gastric cancer cells through regulation of P-gp, Bcl-2 and Bax.

  2007cited by this paper
• The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas.

  2007cited by this paper
• Phase II Study of Irinotecan plus Leucovorin and Bolus 5-Fluorouracil as First- or Second-Line Chemotherapy in Patients with Advanced Gastric or Esophageal-Gastric Junction Adenocarcinoma

  2007cited by this paper
• Esophageal cancer in Central and Eastern Europe: Tobacco and alcohol

  2007cited by this paper
• Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels

  2007cited by this paper
• Correlation between thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level and in vitro chemosensitivity to 5-fluorouracil, in relation to differentiation in gastric cancer

  2007cited by this paper
• Smac/DIABLO and colon cancer.

  2007cited by this paper
• Comparison of pretherapeutic and posttherapeutic expression levels of chemotherapy-associated genes in adenocarcinomas of the esophagus treated by 5-fluorouracil- and cisplatin-based neoadjuvant chemotherapy.

  2007cited by this paper
• Molecular prognostic factors in patients with pancreatic cancer

  2007cited by this paper
• In vivo models for early development of colorectal liver metastasis

  2007cited by this paper
• Second line therapies for the treatment of gastrointestinal stromal tumor

  2007cited by this paper
• Polypoid Spindle Cell Carcinoma of the Esophagus

  2007cited by this paper
• Radiotherapy in gastric cancer: a systematic review of literature and new perspectives

  2007cited by this paper
• Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo

  2007cited by this paper
• Detection of tumor stem cell markers in pancreatic carcinoma cell lines.

  2007cited by this paper
• Docetaxel: in gastric cancer.

  2007cited by this paper
• Chemoprevention of colorectal cancer – a new target needed?

  2007cited by this paper
• Chemotherapy of advanced gastric cancer.

  2007cited by this paper
• Epidemiology of gastric cancer.

  2006cited by this paper
• Expression of transporters potentially involved in the targeting of cytostatic bile acid derivatives to colon cancer and polyps.

  2006cited by this paper
• Rare tumors of the colon and rectum: a national review

  2006cited by this paper
• Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.

  2006cited by this paper
• Etiology and risk factors for oesophageal adenocarcinoma: possibilities for chemoprophylaxis?

  2006cited by this paper
• OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib.

  2006cited by this paper
• Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells.

  2006cited by this paper
• Decrease in c-Myc activity enhances cancer cell sensitivity to vinblastine

  2006cited by this paper
• Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis.

  2006cited by this paper
• Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells.

  2006cited by this paper
• Cancer of the gastric cardia.

  2006cited by this paper
• Gastrointestinal stromal tumours: an update

  2006cited by this paper
• Neoadjuvant chemotherapy with S-1 and CDDP in advanced gastric cancer

  2006cited by this paper
• Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells.

  2006cited by this paper
• p27 downregulation and metallothionein overexpression in gastric cancer patients are associated with a poor survival rate

  2006cited by this paper
• KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

  2006cited by this paper
• c-FLIP inhibits chemotherapy-induced colorectal cancer cell death

  2006cited by this paper
• Activation of Akt and ERK signalling pathways induced by etoposide confer chemoresistance in gastric cancer cells.

  2006cited by this paper
• One Thousand Consecutive Pancreaticoduodenectomies

  2006cited by this paper
• Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.

  2006cited by this paper
• Estimates of the cancer incidence and mortality in Europe in 2006.

  2006cited by this paper
• International comparisons of cumulative risk of oesophagus cancer, from cancer incidence in five continents Vol. VIII.

  2006cited by this paper
• Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy.

  2006cited by this paper
• Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival

  2006cited by this paper
• Surgical management of esophagogastric junction tumors.

  2006cited by this paper
• Primary colorectal lymphomas

  2006cited by this paper
• Current role of surgical therapy in gastric cancer.

  2006cited by this paper
• Glucuronidation of SN-38 and NU/ICRF 505 in human colon cancer and adjacent normal colon.

  2006cited by this paper
• Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications.

  2006cited by this paper
• Chemoresistance in solid tumours.

  2006cited by this paper
• Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity.

  2006cited by this paper
• Prediction of response to neoadjuvant chemotherapy in carcinomas of the upper gastrointestinal tract.

  2006cited by this paper
• Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

  2006cited by this paper
• Intra-arterial infusion of 5-fluorouracil, leucovorin, epirubicin and carboplatin (FLEC regimen) in unresectable pancreatic cancer: results of a ten-year experience.

  2006cited by this paper
• Natural History and Chemotherapy Effectiveness for Advanced Adenocarcinoma of the Small Bowel: A Retrospective Review of 113 Cases

  2006cited by this paper
• Epidemiology and risk factors for pancreatic cancer.

  2006cited by this paper
• Interaction of intestinal nucleoside transporter hCNT2 with amino acid ester prodrugs of floxuridine and 2-bromo-5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole.

  2006cited by this paper
• Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.

  2006cited by this paper
• Expression of chemoresistance-related proteins in alpha-fetoprotein-producing adenocarcinoma of the digestive organs.

  2006cited by this paper
• Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma.

  2005cited by this paper
• Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma

  2005cited by this paper
• Multidrug Resistance Proteins in Gastrointestinal Stromal Tumors: Site-Dependent Expression and Initial Response to Imatinib

  2005cited by this paper
• Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline.

  2005cited by this paper
• Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects.

  2005cited by this paper
• Combined GADD45A and Thymidine Phosphorylase Expression Levels Predict Response and Survival of Neoadjuvant-Treated Gastric Cancer Patients

  2005cited by this paper
• A 10-Year Outcomes Evaluation of Mucinous and Signet-Ring Cell Carcinoma of the Colon and Rectum

  2005cited by this paper
• Black oesophagus—cause?

  2005cited by this paper
• Matrix Metalloproteinases Expression Correlates with Survival in Patients with Esophageal Squamous Cell Carcinoma

  2005cited by this paper
• Capecitabine as adjuvant treatment for stage III colon cancer.

  2005cited by this paper
• Biologic and clinical variations of adenocarcinoma at the esophago–gastric junction: Relevance of a topographic‐anatomic subclassification

  2005cited by this paper
• A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas.

  2005cited by this paper
• Global Cancer Statistics, 2002

  2005cited by this paper
• Risk factors for pancreatic cancer

  2005cited by this paper
• Oesophageal adenoid cystic carcinoma and its management options

  2005cited by this paper
• Multidrug resistance‐associated protein (MRP1) gene is strongly expressed in gastric carcinomas. Analysis by immunohistochemistry and real‐time quantitative RT‐PCR

  2005cited by this paper
• Association of Pretherapeutic Expression of Chemotherapy-Related Genes with Response to Neoadjuvant Chemotherapy in Barrett Carcinoma

  2005cited by this paper
• Concomitant leiomyoma and leiomyosarcoma of the oesophagus.

  2005cited by this paper
• The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence.

  2005cited by this paper
• Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.

  2005cited by this paper
• Epidemiology of esophageal adenocarcinoma

  2005cited by this paper
• Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma.

  2005cited by this paper
• Early Esophageal Cancer: Pattern of Lymphatic Spread and Prognostic Factors for Long-Term Survival After Surgical Resection

  2005cited by this paper
• High Gene Expression of TS1, GSTP1, and ERCC1 Are Risk Factors for Survival in Patients Treated with Trimodality Therapy for Esophageal Cancer

  2005cited by this paper
• ROLE OF ORGANIC ANION TRANSPORTER OATP1B1 (OATP-C) IN HEPATIC UPTAKE OF IRINOTECAN AND ITS ACTIVE METABOLITE, 7-ETHYL-10-HYDROXYCAMPTOTHECIN: IN VITRO EVIDENCE AND EFFECT OF SINGLE NUCLEOTIDE POLYMORPHISMS

  2005cited by this paper

• Advances and Perspectives on Bioelectronic and Atomic Nanogenerators for Anticancer Therapy

  2025cites this paper
• The neuroscience of cancer: Focus on neuropeptidergic systems

  2025cites this paper
• Application of HR CS GF-MAS for Determining the Intracellular Concentration of Fluorinated Drugs and Drug Candidates in Cancer Cells, Using Calcium Monofluoride (CaF) as the Target Molecule

  2025cites this paper
• Development of Dry Powder Inhaler formulation for site specific delivery of nanoconjugates loaded with Curcumin and BCL2 siRNA in Lung Cancer.

  2025cites this paper
• Phytostilbenes in lymphoma: Focuses on the mechanistic and clinical prospects of resveratrol, pterostilbene, piceatannol, and pinosylvin.

  2024cites this paper
• Immunotherapy in gastrointestinal cancers: current strategies and future directions – a literature review

  2024influential citation
• A Combination Therapy of Cyclophosphamide and Immunomodulating Agents in Cancer.

  2024cites this paper
• Anti-cancer Drug Targeting using Stimuli Sensitive Mesoporous Silica Nanoparticle in Colorectal Cancer.

  2024cites this paper
• Effect of short-term fasting on the cisplatin activity in human oral squamous cell carcinoma cell line HN5 and chemotherapy side effects

  2024cites this paper
• Blood-brain barrier penetrating nanosystems enable synergistic therapy of glioblastoma

  2024cites this paper
• Design, synthesis, antiproliferative, antituberculosis and in-silico analysis of New Schiff base derivatives of cyclohepta[b]thiophene

  2024cites this paper
• Manganese-Enriched Zinc Peroxide Functional Nanoparticles for Potentiating Cancer Immunotherapy.

  2023cites this paper
• Thiophene derivative inflicts cytotoxicity via an intrinsic apoptotic pathway on human acute lymphoblastic leukemia cells

  2023cites this paper
• Metal nanoparticles as a potential technique for the diagnosis and treatment of gastrointestinal cancer: a comprehensive review

  2023cites this paper
• A REVIEW ON RECENT ADVANCES ON STIMULI BASED SMART NANOMATERIALS FOR DRUG DELIVERY AND BIOMEDICAL APPLICATION

  2023cites this paper
• Anticancer effect of involucrasin A on colorectal cancer cells by modulating the Akt/MDM2/p53 pathway

  2023cites this paper
• Synthetic biology-inspired cell engineering in diagnosis, treatment and drug development

  2023cites this paper
• Synergistic effects of complex drug combinations in colorectal cancer cells predicted by logical modelling

  2023cites this paper
• Expression of Chemoresistance-Associated ABC Proteins in Hepatobiliary, Pancreatic and Gastrointestinal Cancers

  2022cites this paper
• A Thermodynamic Study on the Interaction between RH-23 Peptide and DMPC-Based Biomembrane Models

  2022cites this paper
• Conquering Cancer Multi-Drug Resistance Using Curcumin and Cisplatin Prodrug-Encapsulated Mesoporous Silica Nanoparticles for Synergistic Chemo- and Photodynamic Therapies

  2022cites this paper
• Smart nanomaterials for cancer diagnosis and treatment

  2022cites this paper
• Cancer: Can CRISPR Become a Game Changer?

  2022cites this paper
• Immunotherapy-based novel nanoparticles in the treatment of gastrointestinal cancer: Trends and challenges

  2022cites this paper
• Potential Role of Herbal- and Bacterial-Derived Peptides Against Colorectal Cancer

  2022cites this paper
• Synthesis, characterization, and biological evaluation of doxorubicin containing silk fibroin micro- and nanoparticles

  2021cites this paper
• Genetically regulated expression underlies cellular sensitivity to chemotherapy in diverse populations.

  2021cites this paper
• Lipidated Peptidomimetic Ligand-Functionalized HER2 Targeted Liposome as Nano-Carrier Designed for Doxorubicin Delivery in Cancer Therapy

  2021cites this paper
• Comparative QM/MM Molecular Dynamics and Umbrella Sampling Simulations: Interaction of the Zinc-Bound Intermediate Gem-Diolate Trapoxin A Inhibitor and Acetyl-l-lysine Substrate with Histone Deacetylase 8.

  2021cites this paper
• Thiophene Derivative‐Loaded Nanoparticles Mediate Anticancer Activity Through the Inhibition of Kinases and Microtubule Assembly

  2021cites this paper
• A pH-sensitive liposome formulation of a peptidomimetic-Dox conjugate for targeting HER2 + cancer.

  2021cites this paper
• Titanium Dioxide Nanoparticles: Prospects and Applications in Medicine

  2020cites this paper
• Cyclohepta[b]thiophenes as Potential Antiproliferative Agents: Design, Synthesis, In Vitro, and In Vivo Anticancer Evaluation.

  2020cites this paper
• Liver and gastrointestinal cancers

  2020cites this paper
• pH-sensitive curcumin conjugated micelles for tumor triggered drug delivery

  2020cites this paper
• Cellular Mechanisms Accounting for the Refractoriness of Colorectal Carcinoma to Pharmacological Treatment

  2020cites this paper
• Comprehensive gene and pathway analysis of cervical cancer progression

  2020cites this paper
• Development of multifunctional cobalt ferrite/hydroxyapatite nanocomposites by microwave assisted wet precipitation method: A promising platform for synergistic chemo-hyperthermia therapy

  2019cites this paper
• Design and synthesis of novel artemisinin derivatives with potent activities against colorectal cancer in vitro and in vivo.

  2019cites this paper
• Antineoplastic therapy - multidrug resistance

  2019cites this paper
• Neocarzinostatin, Aptamer Conjugates for Targeting EpCAM-positive Tumor Cells.

  2017cites this paper
• Synthesis of Novel Hybrids of Thymoquinone and Artemisinin with High Activity and Selectivity Against Colon Cancer

  2017cites this paper
• Bioactive phytochemicals from shoots and roots of Salvia species

  2016cites this paper
• Mechanisms of Resistance to Chemotherapy in Gastric Cancer.

  2016cites this paper
• 10. Hepatocellular carcinoma

  2015cites this paper
• EFFICACY AND SAFETY OF DOCOSAHEXAENOIC ACID ACYLATED PHLORIDZIN FOR TREATING TRIPLE NEGATIVE BREAST CANCER

  2014cites this paper
• Monitoring therapeutic monoclonal antibodies in brain tumor

  2014cites this paper
• Oxaliplatin activates the Keap1/Nrf2 antioxidant system conferring protection against the cytotoxicity of anticancer drugs.

  2014cites this paper
• Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis.

  2013cites this paper
• Cisplatin-induced chemoresistance in colon cancer cells involves FXR-dependent and FXR-independent up-regulation of ABC proteins.

  2012cites this paper
• Molecular bases of liver cancer refractoriness to pharmacological treatment.

  2010cites this paper
• New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives.

  2010cites this paper
• Strategies for overcoming chemotherapy resistance in enterohepatic tumours.

  2010cites this paper
• Clinical Trials of Chinese Medicine for the Treatment of Cancer

  2010cites this paper